Appointments: Gilead, Shield Therapeutics, Gelesis, TG Therapeutics, Aziyo Biologics, Allogene Therapeutics, Mesoblast and CGT Catapult Make New Hires

Gilead Sciences Inc. has promoted Andrew Dickinson to executive vice president, corporate development and strategy, effective immediately. Dickinson will become a member of Gilead’s senior leadership team. Martin Silverstein, executive vice president, strategy, has decided to leave Gilead at the end of August to return to the East Coast. Dickinson joined Gilead in 2016 as senior vice president, corporate development, and led the acquisitions of Kite Pharma Inc. and Cell Design Labs Inc. Before joining Gilead, Dickinson served as global co-head of healthcare investment banking for Lazard. Silverstein will remain at Gilead until the end of August.

Dr Andrew Heath has notified Shield Therapeutics PLC of his intention to step down as chairman, and from the board, by not standing for re-election at the upcoming AGM...